Long-Term Data Reinforce Standard of Care in Unresectable Melanoma

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 19:45, 5 December 2021 by AyoFalade (talk | contribs) (Created page with "https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.9506 Frontline treatment of unresectable melanoma with the immunotherapy combination of nivolumab (Opdivo) and ipili...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.9506

Frontline treatment of unresectable melanoma with the immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) led to an unprecedented median overall survival (OS) of 6 years, an updated analysis of a randomized trial showed.

Retrieved from "https://hemonc.org/w/index.php?title=Long-Term_Data_Reinforce_Standard_of_Care_in_Unresectable_Melanoma&oldid=53416"